The apoB/apoA1 ratio predicts future cardiovascular events in patients with rheumatoid arthritis

References

• Wållberg-Jonsson S, Johansson H, Ohman ML, Rantapaa-Dahlqvist S. Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis. A retrospective cohort study from disease onset. J Rheumatol 1999;26:2562–71.
   PubMed Web of Science ®Google Scholar
• Solomon DH, Karlson EW, Rimm EB, Cannuscio CC, Mandl LA, Manson JE, Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 2003;107:1303–7.
   PubMedGoogle Scholar
• Sodergren A, Karp K, Boman K, Eriksson C, Lundstrom E, Smedby T, Atherosclerosis in early rheumatoid arthritis: very early endothelial activation and rapid progression of intima media thickness. Arthritis Res Ther 2010;12:R158.
   PubMed Web of Science ®Google Scholar
• Avina-Zubieta JA, Thomas J, Sadatsafavi M, Lehman AJ, Lacaille D. Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis 2012;71:1524–9.
   PubMedGoogle Scholar
• Wolfe F, Mitchell DM, Sibley JT, Fries JF, Bloch DA, Williams CA, The mortality of rheumatoid arthritis. Arthritis Rheum 1994;37:481–94.
   PubMedGoogle Scholar
• Wållberg-Jonsson S, Ohman ML, Dahlqvist SR. Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in Northern Sweden. J Rheumatol 1997;24:445–51.
   PubMedGoogle Scholar
• Avina-Zubieta JA, Choi HK, Sadatsafavi M, Etminan M, Esdaile JM, Lacaille D. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum 2008;59:1690–7.
   PubMedGoogle Scholar
• del Rincon ID, Williams K, Stern MP, Freeman GL, Escalante A. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001;44:2737–45.
   PubMedGoogle Scholar
• John H, Kitas G, Toms T, Goodson N. Cardiovascular co-morbidity in early rheumatoid arthritis. Best Pract Res Clin Rheumatol 2009;23:71–82.
   PubMedGoogle Scholar
• Rantapaa-Dahlqvist S, Wållberg-Jonsson S, Dahlen G. Lipoprotein (a), lipids, and lipoproteins in patients with rheumatoid arthritis. Ann Rheum Dis 1991;50:366–8.
   Google Scholar
• Park YB, Lee SK, Lee WK, Suh CH, Lee CW, Lee CH, Lipid profiles in untreated patients with rheumatoid arthritis. J Rheumatol 1999;26:1701–4.
   PubMedGoogle Scholar
• Boers M, Nurmohamed MT, Doelman CJ, Lard LR, Verhoeven AC, Voskuyl AE, Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis. Ann Rheum Dis 2003;62:842–5.
   PubMedGoogle Scholar
• van Halm VP, Nielen MM, Nurmohamed MT, van Schaardenburg D, Reesink HW, Voskuyl AE, Lipids and inflammation: serial measurements of the lipid profile of blood donors who later developed rheumatoid arthritis. Ann Rheum Dis 2007;66:184–8.
   PubMedGoogle Scholar
• Jonsson SW, Backman C, Johnson O, Karp K, Lundstrom E, Sundqvist KG, Increased prevalence of atherosclerosis in patients with medium term rheumatoid arthritis. J Rheumatol 2001;28:2597–602.
   PubMedGoogle Scholar
• van Sijl AM, Peters MJ, Knol DK, de Vet HC, Gonzalez-Gay MA, Smulders YM, Carotid intima media thickness in rheumatoid arthritis as compared to control subjects: a meta-analysis. Semin Arthritis Rheum 2011;40:389–97.
   PubMedGoogle Scholar
• Wållberg-Jonsson S, Dahlen GH, Nilsson TK, Ranby M, Rantapaa-Dahlqvist S. Tissue plasminogen activator, plasminogen activator inhibitor-1 and von Willebrand factor in rheumatoid arthritis. Clin Rheumatol 1993;12:318–24.
   PubMedGoogle Scholar
• Matta F, Singala R, Yaekoub AY, Najjar R, Stein PD. Risk of venous thromboembolism with rheumatoid arthritis. Thromb Haemost 2009;101:134–8.
   PubMedGoogle Scholar
• Zoller B, Li X, Sundquist J, Sundquist K. Risk of pulmonary embolism in patients with autoimmune disorders: a nationwide follow-up study from Sweden. Lancet 2012;379:244–9.
   PubMedGoogle Scholar
• Bacani AK, Gabriel SE, Crowson CS, Heit JA, Matteson EL. Noncardiac vascular disease in rheumatoid arthritis: increase in venous thromboembolic events? Arthritis Rheum 2012;64:53–61.
   PubMedGoogle Scholar
• Jansson JH, Nilsson TK, Johnson O. von Willebrand factor in plasma: a novel risk factor for recurrent myocardial infarction and death. Br Heart J 1991;66:351–5.
   PubMedGoogle Scholar
• Hamsten A, de Faire U, Walldius G, Dahlen G, Szamosi A, Landou C, Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987;2:3–9.
   PubMedGoogle Scholar
• Wållberg-Jonsson S, Cederfelt M, Rantapaa Dahlqvist S. Hemostatic factors and cardiovascular disease in active rheumatoid arthritis: an 8 year followup study. J Rheumatol 2000;27:71–5.
   PubMedGoogle Scholar
• McEntegart A, Capell HA, Creran D, Rumley A, Woodward M, Lowe GD. Cardiovascular risk factors, including thrombotic variables, in a population with rheumatoid arthritis. Rheumatology (Oxford) 2001;40:640–4.
   PubMedGoogle Scholar
• del Rincon I, Freeman GL, Haas RW, O’Leary DH, Escalante A. Relative contribution of cardiovascular risk factors and rheumatoid arthritis clinical manifestations to atherosclerosis. Arthritis Rheum 2005;52:3413–23.
   PubMedGoogle Scholar
• Innala L, Moller B, Ljung L, Magnusson S, Smedby T, Sodergren A, Cardiovascular events in early RA are a result of inflammatory burden and traditional risk factors: a five year prospective study. Arthritis Res Ther 2011;13:R131.
   PubMed Web of Science ®Google Scholar
• Maradit-Kremers H, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE. Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum 2005;52:722–32.
   PubMedGoogle Scholar
• Zannis VI, Chroni A, Krieger M. Role of apoA-I, ABCA1, LCAT, and SR-BI in the biogenesis of HDL. J Mol Med (Berl) 2006; 84:276–94.
   PubMedGoogle Scholar
• Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Atherosclerosis 2012;223:1–68.
   PubMedGoogle Scholar
• Ingelsson E, Schaefer EJ, Contois JH, McNamara JR, Sullivan L, Keyes MJ, Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. J Am Med Assoc 2007;298:776–85.
   Google Scholar
• Hyka N, Dayer JM, Modoux C, Kohno T, Edwards CK 3rd, Roux-Lombard P, Apolipoprotein A-I inhibits the production of interleukin-1beta and tumor necrosis factor-alpha by blocking contact-mediated activation of monocytes by T lymphocytes. Blood 2001;97:2381–9.
   PubMedGoogle Scholar
• Burger D, Dayer JM. High-density lipoprotein-associated apolipoprotein A-I: the missing link between infection and chronic inflammation? Autoimmun Rev 2002;1:111–17.
   Google Scholar
• Ljung L, Olsson T, Engstrand S, Wållberg-Jonsson S, Soderberg S, Rantapaa-Dahlqvist S. Interleukin-1 receptor antagonist is associated with both lipid metabolism and inflammation in rheumatoid arthritis. Clin Exp Rheumatol 2007;25:617–20.
   PubMedGoogle Scholar
• Ropes MW, Bennet GA, Cobb S. Diagnostic criteria for rheumatoid arthritis. Ann Rheum Dis 1959;18:49–53.
   Google Scholar
• Nomenclature and criteria for diagnosis of ischemic heart disease. Report of the Joint International Society and Federation of Cardiology/World Health Organization task force on standardization of clinical nomenclature. Circulation 1979;59:607–9.
   PubMedGoogle Scholar
• Elovson J, Chatterton JE, Bell GT, Schumaker VN, Reuben MA, Puppione DL, Plasma very low density lipoproteins contain a single molecule of apolipoprotein B. J Lipid Res 1988;29: 1461–73.
   PubMedGoogle Scholar
• Rye KA, Barter PJ. Antiinflammatory actions of HDL: a new insight. Arterioscler Thromb Vasc Biol 2008;28:1890–1.
   PubMedGoogle Scholar
• Ajagenova S, Fiskerud R, de Faire U, Hafström I, Frostegård J. Effect of biological therapy on levels of atheroprotective antibodies against phosphorylcholine and apolipoproteins in rheumatoid arthritis – a one year study. Clin Exp Rheumatol 2011;29:942–50.
   PubMedGoogle Scholar
• Ashby DT, Rye KA, Clay MA, Vadas MA, Gamble JR, Barter PJ. Factors influencing the ability of HDL to inhibit expression of vascular cell adhesion molecule-1 in endothelial cells. Arterioscler Thromb Vasc Biol 1998;18:1450–5.
   PubMedGoogle Scholar
• Ajagenova S, Ehrnfelt C, Alizadeh R, Rohani M, Jogestrand T, Hafström I, et al. Longitudinal levels of apolipoproteins and antibodies against phosphorylcholine are independently associated with carotid artery atherosclerosis 5 years after rheumatoid arthritis onset – a prospective cohort study. Rheumatology 2011;50: 1785–93.
   PubMedGoogle Scholar
• Walldius G, Jungner I, Aastveit AH, Holme I, Furberg CD, Sniderman AD. The apoB/apoA-I ratio is better than the cholesterol ratios to estimate the balance between plasma proatherogenic and antiatherogenic lipoproteins and to predict coronary risk. Clin Chem Lab Med 2004;42:1355–63.
   PubMedGoogle Scholar
• Jonsson SW, Ljung L, D’Elia HF, Henrohn D, Turesson C, Svenungsson E. [Cardiovascular risk in inflammatory systemic disease should be assessed regularly. The Swedish Society of Rheumatology has formulated guidelines for primary prevention], in Swedish. Lakartidningen 2012;109:27–9.
   PubMedGoogle Scholar
• Peters MJ, Symmons DP, McCarey D, Dijkmans BA, Nicola P, Kvien TK, EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010;69:325–31.
   PubMedGoogle Scholar
• Doherty NS, Littman BH, Reilly K, Swindell AC, Buss JM, Anderson NL. Analysis of changes in acute-phase plasma proteins in an acute inflammatory response and in rheumatoid arthritis using two-dimensional gel electrophoresis. Electrophoresis 1998;19:355–63.
   PubMedGoogle Scholar
• Park YB, Ahn CW, Choi HK, Lee SH, In BH, Lee HC, Atherosclerosis in rheumatoid arthritis: morphologic evidence obtained by carotid ultrasound. Arthritis Rheum 2002;46:1714–19.
   Google Scholar
• Trocme C, Marotte H, Baillet A, Pallot-Prades B, Garin J, Grange L, Apolipoprotein A-I and platelet factor 4 are biomarkers for infliximab response in rheumatoid arthritis. Ann Rheum Dis 2009;68:1328–33.
   PubMedGoogle Scholar
• Jansson JH, Nilsson TK, Olofsson BO. Tissue plasminogen activator and other risk factors as predictors of cardiovascular events in patients with severe angina pectoris. Eur Heart J 1991;12:157–61.
   PubMedGoogle Scholar
• Daza L, Aguirre M, Jimenez M, Herrera R, Bollain JJ. Common carotid intima-media thickness and von Willebrand factor serum levels in rheumatoid arthritis female patients without cardiovascular risk factors. Clin Rheumatol 2007;26:533–7.
   PubMedGoogle Scholar
• Holmqvist M, Neovius M, Eriksson J, Mantel Ä, Wållberg-Jonsson S, Jacobsson L, et al. Risk of venous thrombembolism in patients with rheumatoid arthritis and the association with disease duration and hospitalization. J Am Med Assoc 2012; 308:1350–6.
   Google Scholar
• Turesson C, McClelland RL, Christianson TJ, Matteson EL. Severe extra-articular disease manifestations are associated with an increased risk of first ever cardiovascular events in patients with rheumatoid arthritis. Ann Rheum Dis 2007;66:70–5.
   PubMedGoogle Scholar